Skip to content
Clinical Trials
Our Network
Our Story
Clinical Trials
Our Network
Our Story
OnCore Login
Clinical Trials
Current Trials
Publications
Our Network
Clinical Trial Working Groups
Sponsor-Investigators
Fostering an Environment of Mentorship
Member Sites
Partners in Research
About
Our Story
Our Team
Annual Reports
Services
Biorepository & Correlative Services
Rapid Accrual
Efficient Timelines for Activation
Regulatory Compliance
Accurate & Relevant Data
News & Events
HCRN Calendar
Oncology Meetings
Make a Difference
Donate Now
Fundraising Events
Advocacy Organizations
Honor Your Hero
Careers
Contact
OnCore Login
network member
Advocate Aurora Research Institute (Illinois)
About Network Member
Enrollment Closed
HCRN-BRE18-334
A Phase II circulating tumor DNA enriched, genomically directed post-neoadjuvant trial for patients with residual triple negative breast cancer (PERSEVERE)
Bryan P. Schneider
Cancer areas:
Breast
Advocate Aurora Research Institute (Illinois)
Aurora Health Care
Froedtert & the Medical College of Wisconsin
Georgetown Lombardi Comprehensive Cancer Center
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Miami Cancer Institute at Baptist Health, Inc.
Novant Health Oncology Specialists
The University of Chicago Medicine Comprehensive Cancer Center
University of Alabama at Birmingham Comprehensive Cancer Center
University of Wisconsin Carbone Cancer Center
UT Health San Antonio MD Anderson Cancer Center
Learn More
See clinicaltrials.gov
Current Trials
Our Network
Our Story
X
